Chemotherapy Effectiveness in Mucinous Ovarian Cancer
Author Information
Author(s): Sandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, Paolo Scollo, Franco Odicino, Gennaro Cormio, Dionyssios Katsaros, Antonella Villa, Liliana Mereu, Fabio Ghezzi, Luigi Manzione, Rossella Lauria, Enrico Breda, Desiderio Gueli Alletti, Michela Ballardini, Alessandra Vernaglia Lombardi, Roberto Sorio, Giorgia Mangili, Domenico Priolo, Giovanna Magni, Alessandro Morabito
Primary Institution: Istituto Nazionale Tumori, Napoli, Italy
Hypothesis
The study aims to evaluate the activity of chemotherapy in patients with platinum-sensitive recurrent mucinous ovarian cancer.
Conclusion
Platinum-sensitive mucinous ovarian cancer has a poor response to chemotherapy.
Supporting Evidence
- Mucinous tumors had a higher number of patients with lower tumor grading.
- Patients with mucinous cancer had a worse performance status at recurrence.
- The response rate to second-line chemotherapy was lower in mucinous cancer compared to non-mucinous cancer.
Takeaway
Mucinous ovarian cancer doesn't respond well to chemotherapy, which means patients might not get better with standard treatments.
Methodology
The study retrospectively assessed patients with recurrent platinum-sensitive ovarian cancer from 37 Italian centers, analyzing data collected between 2000 and 2002.
Potential Biases
The small sample size may limit the generalizability of the findings.
Limitations
The study is retrospective and lacks central pathology review.
Participant Demographics
The study included 20 patients with mucinous ovarian cancer and 388 with other histotypes.
Statistical Information
P-Value
p = 0.0023
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website